Evidence map›Paper›PMID 31048505›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Substrate complex competition is a regulatory motif that allows NFκB RelA to license but not amplify NFκB RelB.

Simon Mitchell, Alexander Hoffmann

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Computational modelling of aggressive B-cell lymphoma.Biochemical Society transactions · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. NF-kB and the CLL microenvironment.Frontiers in oncology · 2023
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Simon MitchellInstitute for Quantitative and Computational Biosciences, University of California, Los Angeles, CA 90095.ORCID 0000-0003-1091-6349
Alexander HoffmannInstitute for Quantitative and Computational Biosciences, University of California, Los Angeles, CA 90095; ahoffmann@ucla.edu.ORCID 0000-0002-5607-3845
QB3 · US

Funding

Cell decision underlying B-cell immune responsesR01AI132731 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HOFFMANN, ALEXANDER · 2018 to 2022
$2.2M
The NFkB System in Dendritic CellsR01AI127867 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HOFFMANN, ALEXANDER · 2018 to 2022
$2.2M
NIAID NIH HHS R01 AI127867NIAID NIH HHS R01 AI132731
6 · The paper itself

Abstract

Signaling pathways often share molecular components, tying the activity of one pathway to the functioning of another. In the NFκB signaling system, distinct kinases mediate inflammatory and developmental signaling via RelA and RelB, respectively. Although the substrates of the developmental, so-called noncanonical, pathway are induced by inflammatory/canonical signaling, crosstalk is limited. Through dynamical systems modeling, we identified the underlying regulatory mechanism. We found that as the substrate of the noncanonical kinase NIK, the nfkb2 gene product p100, transitions from a monomer to a multimeric complex, it may compete with and inhibit p100 processing to the active p52. Although multimeric complexes of p100 (IκBδ) are known to inhibit preexisting RelA:p50 through sequestration, here we report that p100 complexes can inhibit the enzymatic formation of RelB:p52. We show that the dose-response systems properties of this complex substrate competition motif are poorly accounted for by standard Michaelis-Menten kinetics, but require more detailed mass action formulations. In sum, although tonic inflammatory signaling is required for adequate expression of the noncanonical pathway precursors, the substrate complex competition motif identified here can prevent amplification of the active RelB:p52 dimer in elevated inflammatory conditions to ensure reliable RelB-dependent developmental signaling independent of inflammatory context.

Indexed as

Models, ChemicalSignal TransductionTranscription Factor RelATranscription Factor RelBTranscription Factor RelATranscription Factor RelBcrosstalkimmune developmentinflammationNFκB canonical pathwayNFκB noncanonical pathway

Identifiers

PMID31048505
PMCPMC6535030
OpenAlexW2942665504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.